MANIFEST:Pelabresib联合芦可替尼治疗未接受Janus激酶抑制剂治疗的骨髓纤维化
MANIFEST是一项全球、开放标签、非随机、多队列II期研究,纳入未接受JAK抑制剂治疗的骨髓纤维化患者,接受pelabresib联合芦可替尼治疗。24周时68%(57/84)患者达到脾体积缩小≥35%(SVR35),56%(46/82)达到总症状评分降低≥50%(TSS50)。3/4级毒性包括血小板减少(12%)和贫血(35%),3例患者因此停药。
要点
- 24周时SVR35达68%(57/84),48周时SVR35达60%(47/79)。
- 24周时TSS50达56%(46/82),36%患者血红蛋白改善。
- 3/4级贫血35%、血小板减少12%,3例因毒性停药。
核心结论
- 在未接受JAK抑制剂治疗的骨髓纤维化患者中,BET抑制剂pelabresib联合芦可替尼耐受性良好,脾脏和症状负担获得持久改善,并伴有提示潜在疾病修饰活性的生物标志物发现。
研究设计与样本
- MANIFEST(ClinicalTrials.gov标识:NCT02158858)是一项全球、开放标签、非随机、多队列II期研究,纳入未接受JAK抑制剂治疗的骨髓纤维化患者,接受pelabresib联合芦可替尼治疗,主要终点为24周时脾体积缩小≥35%(SVR35)。
主要发现
- 84例患者接受至少1剂pelabresib联合芦可替尼;中位年龄68岁(范围37-85岁);动态国际预后评分系统中危-1占24%、中危-2占61%、高危占16%;66%(55/84)基线血红蛋白<10 g/dL。
- 24周时68%(57/84)达到SVR35,56%(46/82)达到TSS50。
- 24周时36%(29/84)血红蛋白改善(均值1.3 g/dL,中位0.8 g/dL),28%(16/57)纤维化改善≥1级,29.5%(13/44)JAK2V617F突变等位基因分数降低>25%,后者与SVR35应答相关(P=0.018,Fisher精确检验)。
- 48周时60%(47/79)达到SVR35。
- ≥10%患者发生的3/4级毒性为血小板减少(12%)和贫血(35%),导致3例患者终止治疗;95%(80/84)研究参与者继续联合治疗超过24周。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease modification highlight an unmet need. Pelabresib (CPI-0610) is an investigational, selective oral bromodomain and extraterminal domain inhibitor (BETi). METHODS: MANIFEST (ClinicalTrails.gov identifier: NCT02158858), a global, open-label, nonrandomized, multicohort, phase II study, includes a cohort of JAKi-naïve patients with myelofibrosis treated with pelabresib and ruxolitinib. The primary end point is a spleen volume reduction of ≥ 35% (SVR35) at 24 weeks. RESULTS: Eighty-four patients received ≥ 1 dose of pelabresib and ruxolitinib. The median age was 68 (range, 37-85) years; 24% of patients were intermediate-1 risk, 61% were intermediate-2 risk, and 16% were high risk as per the Dynamic International Prognostic Scoring System; 66% (55 of 84) of patients had a hemoglobin level of < 10 g/dL at baseline. At 24 weeks, 68% (57 of 84) achieved SVR35, and 56% (46 of 82) achieved a total symptom score reduction of ≥ 50% (TSS50). Additional benefits at week 24 included 36% (29 of 84) of patients with improved hemoglobin levels (mean, 1.3 g/dL; median, 0.8 g/dL), 28% (16 of 57) with ≥ 1 grade improvement in fibrosis, and 29.5% (13 of 44) with > 25% reduction in JAK2V617F-mutant allele fraction, which was associated with SVR35 response (P = .018, Fisher's exact test). At 48 weeks, 60% (47 of 79) of patients had SVR35 response. Grade 3 or 4 toxicities seen in ≥ 10% patients were thrombocytopenia (12%) and anemia (35%), leading to treatment discontinuation in three patients. 95% (80 of 84) of the study participants continued combination therapy beyond 24 weeks. CONCLUSION: The rational combination of the BETi pelabresib and ruxolitinib in JAKi-naïve patients with myelofibrosis was well tolerated and showed durable improvements in spleen and symptom burden, with associated biomarker findings of potential disease-modifying activity.
引用
- Mascarenhas J, Kremyanskaya M, Patriarca A, et al. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. J Clin Oncol. 2023. PMID: 36881782. doi:10.1200/JCO.22.01972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。